RECRUITING

Investigation of Locus Coeruleus Function in Sustained Attention

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The norepinephrine-producing locus coeruleus (LC) is thought to be central to a wide array of cognitive functions, like attention and goal pursuit, and has been implicated in dysfunctions including attention deficit hyperactivity disorder and schizophrenia. The goal of this proposal is to develop methods that permit measurement of activity in the human LC. Because the LC is small and located in the pons, the Investigators will use high resolution magnetic resonance imaging techniques tailored to the brainstem environment, including neuromelanin-sensitive images shown to delineate the LC, combined with pharmacological manipulation to confirm the location of functional activity.

Official Title

Investigation of Locus Coeruleus Function in Sustained Attention

Quick Facts

Study Start:2023-10-01
Study Completion:2025-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06041048

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Between the ages of 18 - 60 years of age,
  2. * Typically developing, healthy adult
  1. * History of schizophrenia, other forms of psychosis,
  2. * Specific or focal neurological disorder or severe alcohol or drug use disorder within the past 5 years
  3. * History of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants, or who have had recent history of myocardial infarction or unstable angina.
  4. * Volunteers with known hypersensitivity to modafinil or armodafinil or its inactive ingredients
  5. * Known allergy/sensitivity or any hypersensitivity to components of modafinil or its formulation
  6. * Inability to swallow tablets or tolerate oral medication;
  7. * Pregnant or nursing (participants will be required to have a negative pregnancy test)
  8. * Contraindication for MRI scanning (metal implants, pacemakers, metal foreign bodies, or pregnancy)
  9. * Use of psychotropic medication within the past week
  10. * Claustrophobic and not comfortable being in a small space may also not want to participate

Contacts and Locations

Study Contact

Julie Schweitzer, PhD
CONTACT
9167030450
jschweitzer@ucdavis.edu
Jared Borden, MA
CONTACT
9167030294
Jborden@ucdavis.edu

Study Locations (Sites)

University of California, Davis
Sacramento, California, 95817
United States

Collaborators and Investigators

Sponsor: University of California, Davis

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-01
Study Completion Date2025-12-30

Study Record Updates

Study Start Date2023-10-01
Study Completion Date2025-12-30

Terms related to this study

Additional Relevant MeSH Terms

  • Attention - No Condition is Being Assessed - Healthy Adults